FOLD vs. ARWR, BHVN, TPTX, PRGO, BHC, EXAS, RGEN, IONS, HALO, and EXEL
Should you be buying Amicus Therapeutics stock or one of its competitors? The main competitors of Amicus Therapeutics include Arrowhead Pharmaceuticals (ARWR), Biohaven (BHVN), Turning Point Therapeutics (TPTX), Perrigo (PRGO), Bausch Health Companies (BHC), Exact Sciences (EXAS), Repligen (RGEN), Ionis Pharmaceuticals (IONS), Halozyme Therapeutics (HALO), and Exelixis (EXEL). These companies are all part of the "medical" sector.
Arrowhead Pharmaceuticals (NASDAQ:ARWR) and Amicus Therapeutics (NASDAQ:FOLD) are both mid-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, analyst recommendations, media sentiment, earnings, dividends, community ranking, profitability, valuation and risk.
Amicus Therapeutics has higher revenue and earnings than Arrowhead Pharmaceuticals. Amicus Therapeutics is trading at a lower price-to-earnings ratio than Arrowhead Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
Amicus Therapeutics has a net margin of -34.73% compared to Amicus Therapeutics' net margin of -163.32%. Arrowhead Pharmaceuticals' return on equity of -77.08% beat Amicus Therapeutics' return on equity.
Arrowhead Pharmaceuticals has a beta of 0.94, indicating that its share price is 6% less volatile than the S&P 500. Comparatively, Amicus Therapeutics has a beta of 0.71, indicating that its share price is 29% less volatile than the S&P 500.
Arrowhead Pharmaceuticals received 15 more outperform votes than Amicus Therapeutics when rated by MarketBeat users. However, 73.54% of users gave Amicus Therapeutics an outperform vote while only 65.36% of users gave Arrowhead Pharmaceuticals an outperform vote.
In the previous week, Arrowhead Pharmaceuticals had 11 more articles in the media than Amicus Therapeutics. MarketBeat recorded 16 mentions for Arrowhead Pharmaceuticals and 5 mentions for Amicus Therapeutics. Arrowhead Pharmaceuticals' average media sentiment score of 1.13 beat Amicus Therapeutics' score of 0.61 indicating that Amicus Therapeutics is being referred to more favorably in the news media.
Arrowhead Pharmaceuticals currently has a consensus price target of $43.25, indicating a potential upside of 53.42%. Amicus Therapeutics has a consensus price target of $17.57, indicating a potential upside of 72.61%. Given Arrowhead Pharmaceuticals' stronger consensus rating and higher possible upside, analysts plainly believe Amicus Therapeutics is more favorable than Arrowhead Pharmaceuticals.
62.6% of Arrowhead Pharmaceuticals shares are owned by institutional investors. 4.5% of Arrowhead Pharmaceuticals shares are owned by insiders. Comparatively, 2.2% of Amicus Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.
Summary
Amicus Therapeutics beats Arrowhead Pharmaceuticals on 11 of the 18 factors compared between the two stocks.
Get Amicus Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for FOLD and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding FOLD and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Amicus Therapeutics Competitors List
Related Companies and Tools
Free FOLD Stock Alerts